Table 11 definition

Table 11. EMGdi%max signals obtained in the 5 different postures in healthy subjects including the change from the standardised 45 degree posture 100 Table 12: Initial patient baseline characteristics: categorised by physiological and physician led HMV set up 121 Table 13: Patient baseline characteristics: categorised by disease group 122 Table 14: HMV ventilator settings post set up at hospital discharge: categorised by physiological and physician led HMV set up 124 Table 15: HMV ventilator settings post set up at hospital discharge: categorised by disease group 125 Table 16: Comparison between adherence to HMV in the physiological sEMGpara led set up of HMV and the physician led set up of HMV 129 Table 17: Change in gas exchange between the physiological sEMGpara led set up and the physician led set up of HMV during 3 months of therapy 132 Table 18: Changes in neural respiratory drive between the physiological led HMV set up group and the physician led HMV set up group at baseline self-ventilating and baseline HMV set up Table 19: Change in health related quality of life following 3 months of HMV therapy: comparison of physiological HMV set up and physician led HMV set up 140 Table 20: Change visual analogue scales and patient perception of patient ventilator asynchrony questionnaire following 3 months of HMV therapy: comparison of physiological HMV set up and physician led HMV set up 141 Table 21: Total cohort changes in health related questionnaire measures with 3 months of HMV 142 Table 22: Visual analogue scales and patient perception of patient ventilator asynchrony questionnaire 143 Table 23: Changes in HRQL measures comparing the different disease groups post 3 months of HMV 144 Table 24: Comparison of the number of ventilator alterations: comparison of the physician led HMV set up and the physiological led set up of HMV over the 3 months of HMV therapy 147 Table 25: Comparison of the length of hospital stay for initiation of HMV between the physician led HMV set up and the physiological set up of HMV 147 Table 26: Patient baseline characteristics 169 Table 27: Ventilator settings at initiation and 3 months post HMV 170 Table 28: Sleep quality measures recorded from full overnight polysomnography at initiation and 3 months post NIV therapy 171 Table 29: Nocturnal Respiratory Parameters 173 Table 30 : Integrated 2 minute respiratory polygraphy and 10 minute polysomnography data Table 31 Demographics of healthy subjects 199 Table 32: Demographics of COPD pati...

Split View

AI-Powered Contracts

Draft, Review & Redline at the Speed of AI

Get StartedBook a Demo

Table 11. Wealth Quintiles of SF Providers

Table 11. Sleep Mode Power Allowances for Functional Adders Adder Type Connection Max. Data Rate, r Functional Adder Type (Mbit/second) Details Allowance(▇▇▇▇▇) Interface Wired r < 20 Includes: USB 1.x, IEEE 488, IEEE1284/Parallel/ Centronics, RS232 0.2 20 ≤ r < 500 Includes: USB 2.x, IEEE 1394/ FireWire/▇.▇▇▇▇, 100Mb Ethernet 0.4 r ≥ 500 Includes: USB 3.x,1G Ethernet 0.5 Any Includes: Flash memory- card/smart- card readers, camera interfaces, PictBridge 0.2 Fax Modem Any Applies to MFDs only. 0.2 Wireless, Radio- frequency (RF) Any Includes: Bluetooth, 802.11 2.0

Examples of Table 11 in a sentence

• Table 1.1 of this Appendix B specifies the period covered by each Base Year and each Performance Year, and their corresponding Alignment Years.

• In the event that additional licenses are purchased by Client pursuant to a purchase order, the Table 1.1 will be deemed to be updated to include the additional purchased licenses.

• Refer to Table 1-1, to determine the correct ratings for the AC cable, AC fuses, and AC service disconnect switch for the line amperes as listed on the nameplate of the charger for the available AC voltage.

• The key personnel contact names and numbers are summarized in Table 1.1.

• If Purchaser does not terminate such End User or assign such End User to another Pricing Bundle within five days of receipt of notice, Sprint may assign the End User to Pricing Bundle 1 under Section 2.1.1(a), and charge the Bundle 1 Monthly Recurring Charge set forth in Table 1-1, and such End Users will be included in the calculation of Net End Users for such plan and will otherwise be treated as an End User assigned Pricing Bundle 1.

• The key personnel contact names and numbers are summarized in Table 1.1. Engineer’s Representative (ER) (▇▇▇ ▇▇▇▇ & Partners Hong Kong Limited) Chief Resident Engineer ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ 3698 5700 2698 5999 IEC / ENPO (ENVIRON Hong Kong Limited) Independent Environmental Checker ▇▇▇▇▇▇▇ ▇▇▇ 3465 2888 3465 2899 Environmental Project Office Leader ▇.

• Be sure to read the information contained at the links in Table 1.1 below so that you understand your rights and obligations.

• Language: Table 11: MDs in clinical departments, mapped to the nearest appropriate specialty unless otherwise noted.

• If during an Unscheduled Visit the subject is discontinuing the study lenses or discontinuing from the study, the Investigator must conduct Exit procedures according to Table 1-1: Schedule of Study Procedures and Assessments, as possible.

• For each Online Service listed below in Table 11, Customer is provided the right to use the corresponding online disk space for data related to the referential.

More Definitions of Table 11

Table 11. Drug names, the active ingredients of which are mentioned in documents. SELENIUM SULFIDE TOPICAL 2 REBETOL ORAL 6 PROCHLORPERAZINE ORAL 21 PROCHLORPERAZINE RECTAL 15 PROCHLORPERAZINE INJECTION 21 OCTREOTIDE ACETATE INJECTION 6 MISOPROSTOL ORAL 17 ALBUTEROL SULFATE ORAL 10 ALBUTEROL SULFATE INHALATION 7 GENTAMICIN TOPICAL 47 GENTAMICIN INJECTION 64 NALBUPHINE INJECTION 16 ETHOSUXIMIDE ORAL 20 POTASSIUM CITRATE ORAL 13 PYRILAMINE MALEATE ORAL 5 HYZAAR ORAL 6 NIZATIDINE ORAL 6 VEPESID ORAL 6 VEPESID INJECTION 6 NEOSAR INJECTION 5 TARCEVA ORAL 44 MERCAPTOPURINE ORAL 159 CARBAMAZEPINE ORAL 68 RISPERDAL ORAL 7 CLOTRIMAZOLE ORAL 30 CLOTRIMAZOLE TOPICAL 23 CLOTRIMAZOLE VAGINAL 14 SUSTIVA ORAL 7 SECOBARBITAL SODIUM INJECTION 2 SECOBARBITAL SODIUM ORAL 2 PERPHENAZINE ORAL 20 INDOCIN ORAL 5 INDOCIN RECTAL 2 CHANTIX ORAL 2 ALEVE ORAL 2 VERAPAMIL HYDROCHLORIDE ORAL 4 VERAPAMIL HYDROCHLORIDE INJECTION 3 GUANFACINE HYDROCHLORIDE ORAL 1 DEPO-PROVERA INJECTION 1 STAPHCILLIN INJECTION 1 TRILAFON ORAL 1 TRILAFON INJECTION 1 ECONAZOLE NITRATE TOPICAL 4 TRICOR ORAL 7 PROVERA ORAL 3 DILAUDID ORAL 1 PARACORT ORAL 8 LOGEN ORAL 13 CIPROFLOXACIN OPHTHALMIC 17 CIPROFLOXACIN INJECTION 40 CHOLESTYRAMINE ORAL 50 CONCERTA ORAL 1 WARFARIN SODIUM ORAL 6 VITAMIN D ORAL 100 LYRICA ORAL 1 AMOXAPINE ORAL 29 PANRETIN TOPICAL 3 SYMLIN SUBCUTANEOUS 2 FLUMAZENIL INJECTION 12 DRONABINOL ORAL 32 DIPROSONE TOPICAL 1 METICORTEN ORAL 4

Table 11. Annual Income of Tribal People from Forest Produce S. No Income Range Average Revenue of Mahua Flower (Rs.8/Kg) Average Revenu of Mahua Seeds (Rs.15/Kg) Average Revenue (Tendu Leafes) No. of Households Total 1061.33 721.12 466.92 722 Table 12: Annual Income of Tribal People from Other Sources (In Rs.) S. No Income Range Average Revenue(Livestock) Average Revenue (Social Forestry) Average Revenue (Labour Card) Income From Other Sources No. of Households Total 3774.54 180.27 180.27 2067.16 722

Table 11 means the table entitled “Aircraft Information Table 11 to the Purchase Agreement”.

Table 11. Scale Report Breakdown of Bitch as Reference by Relationship week’, proceeds all other measures solely among close friends, while each other relationship is overwhelmingly reported as “never” used.

Table 11. SRR-SEA Indicative Budget for the Period January to December 2013

Table 11. The normality test of the students’ writing in the pre-test and post- test for experimental and control class. Class P Values Α Statement